10 Low Risk High Reward Stocks Set to Triple by 2030

6. Astria Therapeutics, Inc. (NASDAQ:ATXS)

Number of Hedge Fund Holders: 20

Potential upside: 460.22%

Astria Therapeutics, Inc. (NASDAQ:ATXS) is making waves in allergic and immunologic diseases, specifically in hereditary angioedema (HAE) and atopic dermatitis. This biotech company is pushing forward with two main drugs – navenibart for hereditary angioedema (HAE) and STAR-0310 for atopic dermatitis. Where Navenibart is in a critical Phase 3 trial, and STAR-0310 is still in the early clinical development stage.

The company had a turning point in its global ALPHA-ORBIT Phase 3 trial for Navenibart in February. Early results look promising as patients saw their monthly attacks drop by 90-95%, which could make Navenibart a top contender in HAE treatment. Astria Therapeutics, Inc. (NASDAQ:ATXS) expects to see more data from its long-term ALPHA-SOLAR trial around mid-year.

Furthermore, the company’s other pipeline drug, STAR-0310, started Phase 1a trials in January 2025, targeting atopic dermatitis and showing good results in early testing.

On the financial end, the company is well-positioned with $328.1 million in cash as of the end of December 2024, which should keep it running until mid-2027. Astria Therapeutics, Inc. (NASDAQ:ATXS) spent $77.1 million on R&D last year and posted a $94.3 million net loss. Still, the company is set for future growth, with strong cash reserves and a solid pipeline.

With these advances and planned financial steps, Astria Therapeutics, Inc. (NASDAQ:ATXS) remains among the best low risk stocks.